Dupuytren disease starts with a fracture in the hand which in most cases requires surgery. In the Galdakao Hospital during 2006 and early 2007, medical personnel carried out a study to evaluate the effectiveness of a Aquacel wet cure dressing (Hydrofiber Technology, ConvaTec, Bristol-Myers Squibb) in treatment for secondary wounds after surgery to deal with Dupuytren pathology. 52 patients who underwent surgery for Dupuytren pathology were included in this study, in stages from N to IV, using surgical techniques Skoog and Skoog and McCash. Average patient age was 62.8 (range 29-79); 43 (82.7%) were male. Perilesional skin condition improved in 100% of the cases after the use of this dressing. Average time for complete cicatrisation was 2.7 weeks (DE 1.04). Initial pain sensation tied to the wound had a 4.9 average score (evaluated according to an analogical pain scale from 1 to 10). After cure sessions with this dressing, a 1.8 score was registered (for pain reduction of 63%). Adaptation and ease of application of this dressing received an excellent rate in 47 cases or 90.4% and a good rate in 4 cases, or 9.6%. Comfort sensation was rated as excellent by 48 patients, or 92.3% and good by 4 patients, or 7.7%. Removal of this dressing was rated as excellent in 33 cases, or 63.5% and good in 19 cases, or 36.5%. After this wet environment cure, 32 patients, or 61.5% showed good mobility in their hand, acceptable mobility in 14 cases, or 26.9%, and reduced mobility in 5 cases, or 9.6%. Only one case, 7.9%, did not permit an evaluation.
Download full-text PDF |
Source |
---|
Ann Surg Oncol
January 2025
Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives et Hépatiques, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
Clin Exp Dermatol
January 2025
Dermatology department, Dupuytren 2 University Hospital, Limoges, France.
Ann Surg Oncol
January 2025
Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives et Hépatiques, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
Background: The use of multiagent FOLFIRINOX chemotherapy for pancreatic adenocarcinoma in a neoadjuvant setting has been associated with an increased rate of complete pathological response (CPR) after surgery. This study investigated the long-term outcomes of patients with CPR in a multicenter setting to identify prognostic factors for overall survival (OS) and recurrence-free survival (RFS).
Methods: This retrospective cohort study examined biopsy-proven pancreatic adenocarcinomas with CPR after neoadjuvant chemotherapy or chemoradiotherapy and surgery, between January 2006 and December 2023 across 22 French and 2 Belgian centers.
Surg Endosc
January 2025
Department of Gastroenterology and Endoscopy, Edouard Herriot Hospital, 69437, Lyon, France.
Background: Accurate endoscopic characterization of colorectal lesions is essential to predict histology and select the best treatment strategy but remains very difficult. Instead of the recommended endoscopic characterization, many gastroenterologists routinely perform biopsies of the lesion to propose endoscopic resection with or without R0 intent. The aim of this study was to determine which of endoscopic characterization or biopsies, either targeted (TB) or non-targeted (NTB), is the most effective to determine the best treatment strategy for colorectal neoplasia > 2 cm.
View Article and Find Full Text PDFGynecol Oncol
January 2025
Université de Paris Cité, Paris CARPEM Cancer Institute, Paris, France; INSERM UMR-S 1147, University of Paris Cité, Centre de Recherche des Cordeliers, Paris, France.
Objective: To evaluate the prognostic impact of circulating tumor DNA (ctDNA) detection at diagnosis (T0) and its early decrease after one cycle (T1) of neoadjuvant chemotherapy (NACT) in patients with advanced epithelial ovarian cancer (EOC) included in the CHIVA trial (NCT01583322).
Methods: Blood samples were collected at T0 and before each administration of NACT. Circulating tumor DNA detection was performed by next-generation sequencing.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!